Results 191 to 200 of about 54,702 (261)

Association of Proton Pump Inhibitor and Potassium-Competitive Acid Blocker Use With Discontinuation and Intolerance of Oral 5-Aminosalicylic Acid in Patients With Ulcerative Colitis. [PDF]

JGH Open
Otagiri S, Ito T, Yagisawa K, Sugitani A, Maemoto A.   +4 more
europepmc   +1 more source

Toward the harmonization of bioequivalence guidelines in Europe: Commentary on the state of the art and future priorities under ICH M13A for immediate‐release oral forms

British Journal of Clinical Pharmacology, EarlyView.
Domenico Nocera, Giusi Forastiero, Andrea Logreco, Alessia Proietti, Antonio Galluccio, Carlotta Lunghi, Elisabetta Poluzzi, Fabrizio De Ponti   +7 more
wiley   +1 more source

An all‐in‐one fucosylated gold nanocluster probe enables NIR‐II imaging and multi‐mechanistic therapy of acute kidney injury

BMEMat, EarlyView.
This study developed a fucoside‐targeted gold nanocluster probe that enables early NIR‐II imaging and multi‐mechanistic therapy for acute kidney injury, effectively mitigating oxidative stress, modulating inflammatory responses, and inhibiting ferroptosis to improve renal outcomes. Abstract Acute kidney injury (AKI) remains a life‐threatening condition
Ping Zhang, Boning Tan, Suqing Feng, Beibei Gu, Ting Feng, Haiguang Zhu, Jianping Xie, Xun Yuan   +7 more
wiley   +1 more source

Safety of Proton Pump Inhibitor in Paediatrics: A Study Based on EudraVigilance Data. [PDF]

Fundam Clin Pharmacol
Santi Laurini G, Nikitina V, Montanaro N, Motola D.   +3 more
europepmc   +1 more source

Near‐infrared light‐activated aptamer‐based nanoprobe for spatiotemporally resolved detection of L‐lactate in colorectal cancer

BMEMat, EarlyView.
A near‐infrared (NIR) light‐activated “lock‐key” nanodevice is reported for spatiotemporally resolved detection of intratumoral L‐lactate. The system stays silent until deep‐penetrating NIR light remotely unlocks its function, allowing for precise sensing within tumors.
Siyu Pan, Xuanyi Lu, Wenjie Yang, Yunhui Peng, Lingfu Deng, Shuai Zha, Xueyang Fang, Guochen Bao, Lijun Jiang   +8 more
wiley   +1 more source

Efficacy and Safety of Clopidogrel With and Without a Proton Pump Inhibitor: A Systematic Review and Meta-Analysis. [PDF]

Basic Clin Pharmacol Toxicol
Axelsson MAB, Parodi López N, Wikström Jonsson E, Wallerstedt SM.   +3 more
europepmc   +1 more source

Electron compensation‐gated nanomotor for immunomodulation and microenvironment remodeling in bacterial pneumonia therapy

BMEMat, EarlyView.
A nanomotor featuring an “electronic lock” via electron compensation in an Au‐Ag alloy ensures therapeutic precision. Near‐infrared light acts as a key, unlocking on‐demand Ag+ release for synergistic bactericidal action and microenvironment remodeling to potently treat bacterial pneumonia. Abstract Bacterial pneumonia treatment is severely hampered by
Chenglong Xue, Xiaoyu Zhao, Yuqian Wang, Lijin Shi, Qi Shuai   +4 more
wiley   +1 more source

Unique epithelial proliferative transcriptomic signature in proton pump inhibitor-responsive pediatric eosinophilic esophagitis. [PDF]

JCI Insight
Chakraborty S, Sharma A, Marella S, Rizza CF, O'Brien PA, Ganesan V, Idelman G, Min S, Chen M, McCright-Gill T, Gonzalez N, Polydorides AD, Foster PS, Hogan SP, Chehade M.   +14 more
europepmc   +1 more source

Validation of the European Society of Cardiology Ischemic and Bleeding Risk Criteria for Risk Stratification After Endovascular Therapy in Japanese Patients With Lower Extremity Artery Disease

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The European Society of Cardiology (ESC) guidelines for peripheral artery disease recommend antithrombotic strategies based on high ischemic risk (HIR) and high bleeding risk (HBR) criteria. However, their prognostic value in patients with lower extremity artery disease (LEAD) undergoing endovascular therapy (EVT) remains unclear ...
Hirokazu Shimono, Daisuke Kanda, Akihiro Tokushige, Nobuhiro Ito, Yutaro Nomoto, Hiroyuki Tabata, Kenta Ohmure, Takuro Kubozono, Mitsuru Ohishi   +8 more
wiley   +1 more source

Impact of proton pump inhibitor use on immune-related adverse events in patients with non-small cell lung cancer: a retrospective study. [PDF]

BMC Cancer
Miyamoto I, Shimizu T, Hanamura M, Tanaka R, Kusahana R, Nomoto M, Sugaya K, Nakagawa Y, Gon Y.   +8 more
europepmc   +1 more source